Cited by 1,987Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 60 of the 70 references it cites were found in a registry or an index.

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, Cathy A., Hinds, Philip W., Levine, Arnold J.·1989·Cell

Open this paper in CoChat — free account

Abstract

DNA clones of the wild-type p53 proto-oncogene inhibit the ability of E1A plus ras or mutant p53 plus ras-activated oncogenes to transform primary rat embryo fibroblasts. The rare clones of transformed foci that result from E1A plus ras plus wild-type p53 triple transfections all contain the p53 DNA in their genome, but the great majority fail to express the p53 protein. The three cell lines derived from such foci that express p53 all produce mutant p53 proteins with properties similar or identical to transformation-activated p53 proteins. The p53 mutants selected in this fashion (transformation in vitro) resemble the p53 mutants selected in tumors (in vivo). These results suggest that the p53 proto-oncogene can act negatively to block transformation.

Integrity signals

Registry

Crossref · 10.1016/0092-8674(89)90045-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,302
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Self-citation
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J.-Y., Huang, C.-M., Lee, W.-H., Marsilio, E., Paucha, E., & Livingston, D. M. (1988) · Cell · doi:10.1016/0092-8674(88)90559-4 · Cited by 1,459
Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence
Lee, W., Bookstein, R., Hong, F., Young, L.-J., Shew, J., & Lee, E. Y.-H. P. (1987) · Science · doi:10.1126/science.3823889 · Cited by 1,417
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product
Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., & Harlow, E. (1988) · Nature · doi:10.1038/334124a0 · Cited by 1,403
Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248

Show all 70 references

Sorted by citations

Items 201–300 of 999

p53 in colorectal cancer: clinicopathological correlation and prognostic significance
Scott, N., Sagar, P. M., Stewart, J., Blair, G. E., Dixon, M., & Quirke, P. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.74 · Cited by 212
Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation
Kapoor, M., & Lozano, G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2834 · Cited by 209
The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle.
Denko, N. C., Giaccia, A. J., Stringer, J. R., & Stambrook, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5124 · Cited by 209
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2
Iwabuchi, K., Li, B., Massa, H. F., Trask, B. J., Date, T., & Fields, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.26061 · Cited by 206
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.
Halazonetis, T. D., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06199.x · Cited by 211
IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation
Auwerx, J. H., & Sassone‐Corsi, P. (1991) · Cell · doi:10.1016/0092-8674(91)90322-p · Cited by 205
Toxicological and Pathological Applications of Proliferating Cell Nuclear Antigen (PCNA), A Novel Endogenous Marker for Cell Proliferation
Dietrich, D. R. (1993) · Critical Reviews in Toxicology · doi:10.3109/10408449309104075 · Cited by 204
Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55k proteins
Kao, C. C., Yew, P. R., & Berk, A. J. (1990) · Virology · doi:10.1016/0042-6822(90)90148-k · Cited by 202
p53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 204
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 196
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Luna, R. M. D. O., Kapoor, M., Mims, B. H., El‐Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 201
Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin
Rastinejad, F., Conboy, M. J., Rando, T. A., & Blau, H. M. (1993) · Cell · doi:10.1016/0092-8674(93)90320-p · Cited by 197
Mutant p53: it’s not all one and the same
Kennedy, M. C., & Lowe, S. W. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00989-y · Cited by 211
Frequency and structure of p53 rearrangements in human osteosarcoma.
Miller, C. W., Aslo, A., Tsay, C., Slamon, D. J., Ishizaki, K., Toguchida, J., Yamamuro, T., Lampkin, B. C., & Koeffler, H. P. (1990) · PubMed · Cited by 196
20 years studying p53 functions in genetically engineered mice
Donehower, L. A., & Lozano, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2731 · Cited by 196
Wild‐type p53 adopts a ‘mutant’‐like conformation when bound to DNA.
Halazonetis, T. D., Davis, L. J., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05743.x · Cited by 193
The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses
Levine, A. J. (1990) · Virology · doi:10.1016/0042-6822(90)90505-l · Cited by 192
Self-citation
A Genetic Tool Used to Identify Thioredoxin as a Mediator of a Growth Inhibitory Signal
Deiss, L. P., & Kimchi, A. (1991) · Science · doi:10.1126/science.1901424 · Cited by 193
Modulation of p53-Mediated Transcriptional Repression and Apoptosis by the Adenovirus E1B 19K Protein
Sabbatini, P., Chiou, S., Rao, L., & White, E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.1060 · Cited by 191
Levels of p53 protein increase with maturation in human hematopoietic cells.
Kastan, M. B., Radin, A. I., Kuerbitz, S. J., Onyekwere, O. C., Wolkow, C., Civin, C. I., Stone, K. D., Woo, T. Y., Ravindranath, Y., & Craig, R. W. (1991) · PubMed · Cited by 188
The p53 gene and its role in human brain tumors
Bögler, O., Huang, H., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 189
Tumor suppressor genetics
Payne, S. R., & Kemp, C. J. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi223 · Cited by 189
p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma
Shin, D. M., Lee, J., Lippman, S. M., Lee, J. J., Tu, Z. N., Choi, G., Heyne, K., Shin, H. J. C., Ro, J. Y., Goepfert, H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.8.519 · Cited by 186
P53 is a tumor suppressor gene
Levine, A. J., Finlay, C. A., & Hinds, P. W. (2004) · Cell · doi:10.1016/s0092-8674(04)00036-4 · Cited by 185
Self-citation
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. Á., Ortíz-Sánchez, E., & García-Carrancá, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 203
The p53 tumor suppressor gene frequently is altered in gynecologic cancers
Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R. W., Boyd, J. A., & Bast, R. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70414-7 · Cited by 182
Assessment of p53 protein expression in normal, benign, and malignant oral mucosa
Ogden, G. R., Kiddie, R. A., Lunny, D. P., & Lane, D. P. (1992) · The Journal of Pathology · doi:10.1002/path.1711660411 · Cited by 184
Two Domains of p53 Interact with the TATA-Binding Protein, and the Adenovirus 13S E1A Protein Disrupts the Association, Relieving p53-Mediated Transcriptional Repression
Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R. S., & Shenk, T. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.227 · Cited by 182
Self-citation
Biological and clinical importance of the p53 tumor suppressor gene
Velculescu, V. E., & El‐Deiry, W. S. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.6.858 · Cited by 175
p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study
Ostrowski, J. L., Sawan, A., Henry, L., Wright, C. J., Henry, J. A., Hennessy, C., Lennard, T. W. J., Angus, B., & Horne, C. H. W. (1991) · The Journal of Pathology · doi:10.1002/path.1711640113 · Cited by 180
Mammalian p53 can function as a transcription factor in yeast
Scharer, E., & lggo, R. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.7.1539 · Cited by 177
Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung
Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., & Sekiya, T. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90351-w · Cited by 177
Essential role of p53 in phenethyl isothiocyanate-induced apoptosis.
Huang, C., Ma, W., Li, J., Hecht, S. S., & Dong, Z. (1998) · PubMed · Cited by 176
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
Wright, C. J., Mellon, K., Johnston, P., Lane, D. P., Harris, A. L., Horne, C., & Neal, D. E. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.211 · Cited by 176
P53 gene mutations in acute myeloid leukemia with 17p monosomy
Fenaux, P., Jonveaux, P., Quiquandon, I., Laï, J., Jm, P., Mh, L.-L., Bauters, F., Berger, R., & Kerckaert, J. (1991) · Blood · doi:10.1182/blood.v78.7.1652.1652 · Cited by 175
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium.
Firestein, G. S., Nguyen, K., Aupperle, K. R., Yeo, M., Boyle, D. L., & Zvaifler, N. J. (1996) · Europe PMC (PubMed Central) · Cited by 172
Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products
Levine, A. J. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90015-s · Cited by 173
Self-citation
Transformation of Human and Murine Fibroblasts without Viral Oncoproteins
Boehm, J. S., Hession, M. T., Bulmer, S. E., & Hahn, W. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6464-6474.2005 · Cited by 171
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes
Hubbert, N. L., Sedman, S. A., & Schiller, J. T. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6237-6241.1992 · Cited by 172
Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver
McClung, J. K., Danner, D. B., Stewart, D. A., Smith, J. R., Schneider, E. L., Lumpkin, C. K., Dell’Orco, R. T., & Nuell, M. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91813-5 · Cited by 172
Inhibition of viral and cellular promoters by human wild-type p53
Subler, M. A., Martin, D. W., & Deb, S. (1992) · Journal of Virology · doi:10.1128/jvi.66.8.4757-4762.1992 · Cited by 171
Allelotype study of primary hepatocellular carcinoma.
Fujimori, M., Tokino, T., Hino, O., Kitagawa, T., Imamura, T., Okamoto, E., Mitsunobu, M., Ishikawa, T., Nakagama, H., & Harada, H. (1991) · PubMed · Cited by 170
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
Self-citation
p53, c-erbB-2 and the Epidermal Growth Factor Receptor in the Benign and Malignant Prostate
Mellon, K., Thompson, S., Charlton, R., Marsh, C., Robinson, M., Lane, D. P., Harris, A. L., Horne, C. H. W., & Neal, D. E. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37287-7 · Cited by 169
Tumor suppressor genes
Levine, A. J. (1990) · BioEssays · doi:10.1002/bies.950120203 · Cited by 168
Self-citation
Mdm-2: “big brother” of p53
Momand, J. A., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3 · Cited by 167
The p53 tumor suppressor protein, a modulator of cell proliferation.
Ullrich, S. J., Anderson, C. W., Mercer, W. E., & Appella, E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49524-0 · Cited by 165
Epigallocatechin-3-gallate induces apoptosis in estrogen receptor–negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation
Roy, A. M., Baliga, M. S., & Katiyar, S. K. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.81.4.1 · Cited by 168
The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer.
Sato, T., Saito, H., Swensen, J. J., Olifant, A., Wood, C., Danner, D. B., Sakamoto, T., Takita, K.-I., Kasumi, F., & Miki, Y. (1992) · PubMed · Cited by 164
The specificity of p53 mutation spectra in sunlight induced human cancers
Daya–Grosjean, L., Dumaz, N., & Sarasin, A. R. (1995) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/1011-1344(95)07130-t · Cited by 162
Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene.
Amson, R. B., Nemani, M., Roperch, J.-P., Israeli, D., Bougueleret, L., Gall, I. L., Medhioub, M., Linares‐Cruz, G., Lethrosne, F., Pasturaud, P., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3953 · Cited by 165
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
E2F-1:DP-1 Induces p53 and Overrides Survival Factors To Trigger Apoptosis
Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambetti, G. P., & Cleveland, J. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6864 · Cited by 163
Mutations of p53 gene and their relation to disease progression in B- cell lymphoma
Ichikawa, A., Hotta, T., Takagi, N., Tsushita, K., Kinoshita, T., Nagai, H., Murakami, Y., Hayashi, K., & Saito, H. (1992) · Blood · doi:10.1182/blood.v79.10.2701.2701 · Cited by 161
Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line
Law, J. C., Ritke, M. K., Yalowich, J. C., Leder, G. H., & Ferrell, R. E. (1993) · Leukemia Research · doi:10.1016/0145-2126(93)90161-d · Cited by 162
Involvement of p53 in cell differentiation and development
Almog, N., & Rotter, V. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00012-7 · Cited by 163
Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck
Field, J. K. (1992) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/0964-1955(92)90016-t · Cited by 162
p53 Domains: Structure, Oligomerization, and Transformation
Wang, P., Reed, M. J., Wang, Y., Mayr, G. A., Stenger, J. E., Anderson, M. E., Schwedes, J. F., & Tegtmeyer, P. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5182-5191.1994 · Cited by 161
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
Ahuja, H., Bar‐Eli, M., Arlin, Z. A., Advani, S. H., Allen, S. L., Goldman, J. M., Snyder, D., Foti, A., & Cline, M. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115234 · Cited by 159
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160
Cancer genetics
Knudson, A. G. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10320 · Cited by 160
Involvement of wild-type p53 in pre-B-cell differentiation in vitro.
Shaulsky, G., Goldfinger, N., Peled, A., & Rotter, V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8982 · Cited by 160
How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Chan, W. M., Siu, W. Y., Lau, A. W. S., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 159
The MCK enhancer contains a p53 responsive element.
Weintraub, H. M., Hauschka, S. D., & Tapscott, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4570 · Cited by 159
Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions
Khan, H. Z., Reale, M., Ullah, H., Sureda, A., Tejada, S., Wang, Y., Zhang, Z., & Xiao, J. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.007 · Cited by 157
P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors
Dushku, N., & Reid, T. W. (1997) · Current Eye Research · doi:10.1076/ceyr.16.12.1179.5036 · Cited by 157
p53 represses ribosomal gene transcription
Budde, A., & Grummt, I. (1999) · Oncogene · doi:10.1038/sj.onc.1202402 · Cited by 157
Inactivation of p53 gene in human and murine osteosarcoma cells
Chandar, N., Billig, B., McMaster, J. H., & Novak, J. F. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.43 · Cited by 157
p53 mutations occur in aggressive breast cancer.
Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., & Theillet, C. G. (1992) · PubMed · Cited by 156
Probing the structure, function, and interactions of the Escherichia coli H-NS and StpA proteins by using dominant negative derivatives
Williams, R. M., Rimsky, S., & BUC, H. C. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.15.4335-4343.1996 · Cited by 155
Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Havrilesky, L. J., Darcy, K. M., Hamdan, H. B., Priore, R. L., Leon, J., Bell, J., & Berchuck, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.052 · Cited by 156
Oncogenic potential of the adenovirus E4orf6 protein.
Moore, M., Horikoshi, N., & Shenk, T. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11295 · Cited by 154
Apoptosis, cancer and the p53 tumour suppressor gene
Lee, J. M., & Bernstein, A. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00665797 · Cited by 149
Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas.
Campo, E., Calle-Martin, O. D. L., Miquel, R., Palacín, A., Romero, M., Fabregat, Vives, J., Cardesa, A., & Yagüe, J. (1991) · PubMed · Cited by 153
Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D. W., Ikenega, M., Imura, H., & Ishizaki, K. (1993) · PubMed · Cited by 152
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 159
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutations in pituitary adenomas: rare events
Levy, A., Hall, L., Yeudall, W. A., & Lightman, S. L. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02797.x · Cited by 148
Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein.
Shen, Y. H., & Shenk, T. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8940 · Cited by 148
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148
The p53 tumor suppressor gene in breast cancer
Elledge, R. M., & Allred, D. C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666204 · Cited by 147
The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin
Zhang, H.-Y., Han, Q.-W., Xu, Y.-F., Fan, Y.-R., Dai, Q.-M., Zhu, H.-W., Rong, Z.-G., Wang, J.-J., & Xu, G.-X. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1442 · Cited by 147
The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder Cancer
Smith, N. D., Rubenstein, J. N., Eggener, S. E., & Kozlowski, J. M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000056085.58221.80 · Cited by 147
p53 allele losses, mutations and expression in breast cancer and their relationship to clinico‐pathological parameters
Thompson, A. M., Anderson, T. J., Condie, A., Prosser, J., Chetty, U., Carter, D. C., Evans, H. J., & Steel, C. M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500405 · Cited by 146
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.
Sun, Y., Hegamyer, G. A., Cheng, Y. J., Hildesheim, A., Chen, J. Y., Chen, I.-H., Cao, Y., Yao, K., & Colburn, N. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6516 · Cited by 143
Identifying Tumor Suppressor Genes in Human Colorectal Cancer
Stanbridge, E. J. (1990) · Science · doi:10.1126/science.2403692 · Cited by 143
Control of gene expression by proteolysis
Pahl, H. L., & Baeuerle, P. A. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80007-x · Cited by 141
p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder
Serth, J., Kuczyk, M., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K., & Udo Jonas, A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.41 · Cited by 142
Induction of Growth Arrest by a Temperature-Sensitive p53 Mutant Is Correlated with Increased Nuclear Localization and Decreased Stability of the Protein
Ginsberg, D., Michael, D., Ginsberg, D., & Oren, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.582 · Cited by 142
A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma.
Yamakawa, K., Morita, R., Takahashi, E., Hori, T., Ishikawa, J., & Nakamura, Y. (1991) · PubMed · Cited by 142
p53 over‐expression is an early event in the development of human squamous‐cell carcinoma of the larynx: Genetic and prognostic implications
Dolcetti, R., Doglioni, C., Maestro, R., Gasparotto, D., Barzan, L., Pastore, A. L., Romanelli, M. M. C., & Boiocchi, M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520204 · Cited by 142
Expression of p53 protein in infiltrating and in‐situ breast carcinomas
Walker, R. A., Dearing, S. J., Lane, D. P., & Varley, J. M. (1991) · The Journal of Pathology · doi:10.1002/path.1711650303 · Cited by 141
p53 Mutations in sporadic adrenocortical tumors
Ohgaki, H., Kleihues, P., & Heitz, P. U. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540310 · Cited by 139
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformationPreprint
Boiko, A. D., Porteous, S., Razorenova, O. V., Krivokrysenko, V. I., Williams, B. R. G., & Gudkov, A. V. (2006) · Genes & Development · doi:10.1101/gad.1372606 · Cited by 139
Understanding p53 functions through p53 antibodies
Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 139
Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation
Katiyar, S. K., Roy, A. M., & Baliga, M. S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.207.4.2 · Cited by 139
Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.
Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P. K., Yeargin, J., & Haas, M. (1994) · PubMed Central · Cited by 135
p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas
Wadayama, B., Toguchida, J., Yamaguchi, T., Sasaki, M., & Yamamuro, T. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.493 · Cited by 138
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.
Chen, L., Neubauer, A., Kurisu, W., Waldman, F. M., Ljung, B., Goodson, W. H., Goldman, E. S., Moore, D. H., Balázs, M., & Liu, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3847 · Cited by 140

Authors: Finlay, C. A., Hinds, P. W., & Levine, A. J.
Affiliations: Princeton University (US)
ORCID: Hinds, Philip W.
Levine, Arnold J.
Venue: Cell
Publisher: Elsevier BV
Published: 1989-06
Volume: 57
Issue: 7
Pages: 1083-1093
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/0092-8674(89)90045-7
OpenAlex: W2163565167
Cited by: 1,987
References: 70
Citations by year: 2026: 14 · 2025: 12 · 2024: 25 · 2023: 27 · 2022: 20 · 2021: 34 · 2020: 37 · 2019: 31 · 2018: 29 · 2017: 29 · 2016: 28 · 2015: 12 · 2014: 28 · 2013: 26 · 2012: 38
FWCI: 79.38
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA041086, P01-CA41086-03)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: tumor suppressor, oncogenic transformation, adenovirus E1A, oncogenic Ras, mutant p53, p53 expression, rat embryo fibroblasts, transformed foci, tumor suppressor function
MeSH terms: Animals, Antigens, Polyomavirus Transforming, Cell Line, Cell Transformation, Neoplastic, Cells, Cultured, Gene Expression Regulation, Neoplasm Proteins, Oncogene Proteins, Viral, Phosphoproteins, Proto-Oncogene Proteins, Genes, ras, Transfection, Tumor Suppressor Protein p53, Adenovirus Early Proteins, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The p53 proto-oncogene can act as a suppressor of transformation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks